A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

The objective of this study was to determine the objective response rate in patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer to treatment with trabectedin (Yondelis®) administered as a 3-h infusion weekly for 3 weeks of a 4-week cycle. We carried out a multicentre Pha...

Descripción completa

Detalles Bibliográficos
Autores principales: Krasner, C N, McMeekin, D S, Chan, S, Braly, P S, Renshaw, F G, Kaye, S, Provencher, D M, Campos, S, Gore, M E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360276/
https://www.ncbi.nlm.nih.gov/pubmed/18000504
http://dx.doi.org/10.1038/sj.bjc.6604088

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360276/
https://www.ncbi.nlm.nih.gov/pubmed/18000504
http://dx.doi.org/10.1038/sj.bjc.6604088

Ejemplares similares